| Autor: |
Yoshiro Horai, Toshimasa Shimizu, Akitomo Okadae, Junichi Tokumitsu, Toshiyuki Ikeoka, Genpei Kuriya, Nozomi Iwanaga, Yasumori Izumi, Tomoki Origuchi, Atsushi Kawakami |
| Předmět: |
|
| Zdroj: |
Modern Rheumatology; Jul2022, Vol. 32 Issue 4, p830-833, 4p |
| Abstrakt: |
DPP4is were most commonlyprescribed for pre-existing DM in patients with RS3PEsyndrome: half (9/18, 50.0%) of the patients with RS3PE withpre-existing DM had been receiving DPP4is since the time ofdiagnosis of RS3PE. Rapid Communication KEYWORDS: KEYWORDS: Diabetes mellitus; dipeptidyl peptidase-4 inhibitors; erythrocyte sedimentation rate; inflammation; remitting seronegative symmetrical synovitis with pitting oedema syndrome EN Diabetes mellitus dipeptidyl peptidase-4 inhibitors erythrocyte sedimentation rate inflammation remitting seronegative symmetrical synovitis with pitting oedema syndrome Remitting seronegative symmetrical synovitis with pittingoedema (RS3PE) is elderly-onset symmetrical polysynovitis ofacute onset with pitting oedema in the extremities [1]; theclinical characteristics of this syndrome overlap with thoseof elderly-onset rheumatoid arthritis (RA) and polymyalgiarheumatica [2]. Therefore, clinicians should carefullymonitor glycaemic control in patients with RS3PE syndromeand pre-existing DM and other RDs and consider switchingfrom DPP4is to more promising antidiabetic therapies, suchas glucagon-like peptidase 1 receptor agonists and insulin, incase of poor glycaemic control. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
